Encube Ethicals Private Limited — Diclofenac Exporter Profile
Indian Pharmaceutical Exporter · #7 for Diclofenac · $10.1M export value · DGFT Verified
Encube Ethicals Private Limited is the #7 Indian exporter of Diclofenac with $10.1M in export value and 201 verified shipments. Encube Ethicals Private Limited holds a 2.8% market share in Diclofenac exports across 2 countries. The company exports 11 pharmaceutical products worth $57.5M across 9 therapeutic categories.
Encube Ethicals Private Limited — Diclofenac Export Profile: Buyers & Destinations
Where Does Encube Ethicals Private Limited Export Diclofenac?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $9.4M | 222 | 100.0% |
| SPAIN | $24 | 2 | 0.0% |
Encube Ethicals Private Limited exports Diclofenac to 2 countries. The largest destination is UNITED STATES accounting for 100.0% of Encube Ethicals Private Limited's Diclofenac shipments. These destinations reflect Encube Ethicals Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Diclofenac from Encube Ethicals Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AIM RX 3PL, LLC | UNITED STATES | $4.2M | 92 |
| CARDINAL HEALTH | UNITED STATES | $1.7M | 50 |
| AIM RX 3PL,LLC | UNITED STATES | $1.1M | 23 |
| IPD, SC, USA | UNITED STATES | $893.2K | 21 |
| AIM RX 3PL LLC | UNITED STATES | $563.4K | 13 |
| CHATTEM, INC. | UNITED STATES | $463.8K | 10 |
| IPD SC USA | UNITED STATES | $229.0K | 6 |
| CHATTEM INC | UNITED STATES | $124.9K | 3 |
| INNOVUS PHARMACEUTICALS, INC. | UNITED STATES | $50.0K | 1 |
| SOLA PHARMACEUTICALS | UNITED STATES | $35.1K | 1 |
Encube Ethicals Private Limited supplies Diclofenac to 13 buyers globally. The largest buyer is AIM RX 3PL, LLC (UNITED STATES), followed by CARDINAL HEALTH (UNITED STATES) and AIM RX 3PL,LLC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Diclofenac Export Value and How Much Does Encube Ethicals Private Limited Contribute?
India exported $119.5M worth of Diclofenac through 15,000 shipments from 1007 suppliers to 173 countries, serving 2,731 buyers globally. Encube Ethicals Private Limited contributes $10.1M to this total, accounting for 2.8% of India's Diclofenac exports. Encube Ethicals Private Limited ships Diclofenac to 2 countries through 13 buyers.
What Is the Average Shipment Value for Encube Ethicals Private Limited's Diclofenac Exports?
Encube Ethicals Private Limited's average Diclofenac shipment value is $50.0K per consignment, based on 201 shipments totaling $10.1M. The largest destination is UNITED STATES (100.0% of Encube Ethicals Private Limited's Diclofenac exports).
How Does Encube Ethicals Private Limited Compare to Other Indian Diclofenac Exporters?
Encube Ethicals Private Limited ranks #7 among 1007 Indian Diclofenac exporters with a 2.8% market share. The top 3 exporters are CIPLA LIMITED ($20.9M), TROIKAA PHARMACEUTICALS LIMITED ($16.0M), CAPLIN POINT LABORATORIES LIMITED ($15.5M). Encube Ethicals Private Limited processed 201 shipments to 2 destination countries.
What Diclofenac Formulations Does Encube Ethicals Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DICLOFENAC SODIUM TOPICAL GEL 1% LAMI 10 | $6.3M | 144 |
| DICLOFENAC SODIUM TOPICAL GEL 1 % LAMI 1 | $201.0K | 5 |
| DICLOFENAC SODIUM TOPICAL GEL 1% USP 100 | $200.0K | 4 |
| DICLOFENAC SODIUM TOPICAL GEL 1% USP 100G-OTC B.NO. 3KA39 TO 3KA44 MFG DATE DEC2023 EXP DT.NOV 2025NOS | $104.1K | 3 |
| DICLOFENAC SODIUM TOPICAL GEL 1% USP 100G-OTC B.NO. 3KA45 TO 3KA41 MFG DATE DEC2023 EXP DT.NOV 2025NOS | $104.0K | 3 |
| DICLOFENAC SODIUM TOPICAL GEL 1% 100G ASPERCREME BATCH No.3LW01 MANUFACTURING dateOCT 2023 EXP date SEP 2025 | $100.0K | 2 |
| DICLOFENAC SODIUM TOPICAL GEL 1% USP 100G-OTC BATCH NO.4KA04, 4KA05 MFG.JAN 2024EXP.DEC 2025NOS | $56.9K | 3 |
| DICLOFENAC SODIUM TOPICAL GEL 1 LAMI 100G BATCH NO 3BP88 3BP87 3BP86 3BP81 MFG DT FEB 2023 EXP DT JAN 2025 | $50.0K | 1 |
| DICLOFENAC SODIUM TOPICAL GEL 1 LAMI 100G BATCH NO 3BP88 3BP85 3BP89 3BP91 3BP90 MFG DT FEB 2023 EXP DT JAN | $50.0K | 1 |
| DICLOFENAC SODIUM TOPICAL GEL 1 LAMI 100G BATCH NO 3BP91 3BP93 3BP92 MFG DT FEB 2023 EXP DT JAN 2025 | $50.0K | 1 |
Encube Ethicals Private Limited exports 65 distinct Diclofenac formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DICLOFENAC SODIUM TOPICAL GEL 1% LAMI 10 with 144 shipments worth $6.3M.
Regulatory Requirements: Exporting Diclofenac to Key Markets
What Encube Ethicals Private Limited must comply with to export Diclofenac to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Encube Ethicals Private Limited Compare to Nearest Diclofenac Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | CAPLIN POINT LABORATORIES LIMITED | $15.5M | 310 | 9 | $50.0K |
| 2 | COMBITIC GLOBAL CAPLET PRIVATE LIMITED | $10.8M | 216 | 4 | $50.0K |
| 7 | ENCUBE ETHICALS PRIVATE LIMITED ★ | $10.1M | 201 | 2 | $50.0K |
| 1 | LINCOLN PHARMACEUTICALS LTD | $8.9M | 179 | 22 | $50.0K |
| 8 | MICRO LABS LIMITED | $8.8M | 177 | 18 | $50.0K |
Encube Ethicals Private Limited ranks #7 among 1007 Indian Diclofenac exporters. Average shipment value of $50.0K compared to the market average of $118.7K. The closest competitors by value are CAPLIN POINT LABORATORIES LIMITED and COMBITIC GLOBAL CAPLET PRIVATE LIMITED.
Which Indian Ports Ship Diclofenac Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 2,481 | 16.5% |
| JNPT/ NHAVA SHEVA SEA | 1,272 | 8.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,186 | 7.9% |
| SAHAR AIR | 903 | 6.0% |
| JNPT | 712 | 4.7% |
| DELHI AIR CARGO ACC (INDEL4) | 679 | 4.5% |
| NHAVA SHEVA | 676 | 4.5% |
| Bombay Air | 491 | 3.3% |
Geopolitical & Trade Policy Impact on Encube Ethicals Private Limited's Diclofenac Exports
Encube Ethicals' export operations are influenced by a complex interplay of geopolitical events and international trade policies. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Encube, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.
Conversely, the U.S.-China trade tensions have created opportunities for Indian pharmaceutical companies to capture a larger share of the U.S. market. Encube, with its FDA-approved facilities and established presence in the U.S., is well-positioned to leverage this shift. Additionally, the India-European Union Free Trade Agreement (FTA), concluded in January 2026, aims to eliminate tariffs on pharmaceuticals, thereby enhancing market access for Indian exporters. However, compliance with the EU's stringent regulatory standards, including the Falsified Medicines Directive, remains a critical factor for success in this market.
Encube Ethicals Private Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for Encube Ethicals. The company's adherence to FDA, WHO, and EU Good Manufacturing Practices (GMP) ensures the quality and safety of its products, facilitating access to global markets. The evolving regulatory landscape, particularly in the EU, necessitates continuous investment in quality systems and processes. For instance, the EU's requirement for analytical testing of every batch at the port of destination can delay market entry by two to three months. Proactive engagement with regulatory bodies and investment in compliance infrastructure are essential for mitigating such challenges.
About Encube Ethicals Private Limited
Encube Ethicals Private Limited exports 11 products worth $57.5M. Beyond Diclofenac, top products include Clindamycin, Clotrimazole, Ketoconazole, Sodium, Miconazole. View the complete Encube Ethicals Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Diclofenac — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Diclofenac shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Encube Ethicals Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 224 individual customs records matching Encube Ethicals Private Limited exporting Diclofenac, covering 65 formulations to 2 countries via 13 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 173+ countries, 2,731+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Diclofenac Export Data from Encube Ethicals Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Encube Ethicals Private Limited's Diclofenac exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Encube Ethicals Private Limited
Full Company Profile →
11 products · $57.5M total trade · 9 categories
Diclofenac Stats
Company Overview
Top Products by Encube Ethicals Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Encube Ethicals Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Diclofenac. For current shipment-level data, contact TransData Nexus.